Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459121 | 0.88 | NOTUM (0.40) | PIK3CANOTUM | |
| SCHEMBL19625275 | 0.83 | L3MBTL1 (0.38) | NOTUMCNR2ALDH1A1 | |
| SCHEMBL13141206 | 0.81 | NOTUM (0.36) | NOTUM | |
| SCHEMBL13179082 | 0.80 | TRPV3 (0.36) | NOTUMMAPTALDH1A1 | |
| SCHEMBL21981194 | 0.80 | TRPV3 (0.36) | NOTUMMAPTALDH1A1 | |
| SCHEMBL6919321 | 0.77 | MAPK1 (0.46) | PIK3CDPIK3CANOTUMMAPK1 | |
| SCHEMBL26152350 | 0.77 | OPRL1 (0.41) | PIK3CAMAPTCNR2MAPK1 | |
| SCHEMBL23997051 | 0.76 | CNR2 (0.42) | MAPTCNR2LRRK2ALDH1A1 | |
| SCHEMBL25292351 | 0.76 | CHRNB2 (0.34) | — | |
| SCHEMBL23997050 | 0.75 | CNR2 (0.43) | CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | PDE9A 348/4885PIK3CD 2617/4885PIK3CA 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.